Pathological identification of HER2-low breast cancer: Tips, tricks, and troubleshooting for the optimal test

Pathological identification of HER2-low breast cancer: Tips, tricks, and troubleshooting for the optimal test

The introduction of novel anti-HER2 antibody-drug conjugates (ADC) for the treatment of HER2-low breast cancers has transformed the traditional dichotomy of HER2 status to an expanded spectrum. However, the identification of HER2-low (i.e., immunohistochemistry (IHC) score 1 + or IHC score 2+, witho...

Full description

Bibliographic Details
Main Authors: Elham Sajjadi, Elena Guerini-Rocco, Elisa De Camilli, Oriana Pala, Giovanni Mazzarol, Konstantinos Venetis, Mariia Ivanova, Nicola Fusco
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-04-01
Series:Frontiers in Molecular Biosciences
Subjects:
breast cancer
HER2
HER2-low
pathology
precision medicine
immunohistochemistry
Online Access:https://www.frontiersin.org/articles/10.3389/fmolb.2023.1176309/full

Internet

https://www.frontiersin.org/articles/10.3389/fmolb.2023.1176309/full

Similar Items